Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00544882 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT00544882 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 61 participants.
The verdict
NCT00544882, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a multi-center study to evaluate hormone levels with the oral contraceptive regimen DR-1021.
Interventions
- DRUG DR-1021
- DRUG Mircette®
- DRUG Kariva®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-10-31 |
| Est. Completion | 2008-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00544882
The ClinicalTrials.gov registry entry for NCT00544882 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DR-1021 is the first listed.
NCT00544882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00544882 about?
NCT00544882 is a clinical study titled "A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021". This is a multi-center study to evaluate hormone levels with the oral contraceptive regimen DR-1021.
What is the current status of trial NCT00544882?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2007-10-31. Estimated completion is 2008-03-31.
What interventions are being tested in trial NCT00544882?
The interventions under investigation include: DR-1021 (DRUG), Mircette® (DRUG), Kariva® (DRUG).
Who is sponsoring clinical trial NCT00544882?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.